Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;33(5):e2464.
doi: 10.1002/rmv.2464. Epub 2023 Jun 15.

SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges

Mingtao Liu  1 , Zhiman Liang  1 , Zhangkai J Cheng  1 , Li Liu  2 , Qiwen Liu  2 , Yiyin Mai  2 , Huihuang Chen  2 , Baoying Lei  2 , Shangwei Yu  2 , Huihui Chen  2 , Peiyan Zheng  1 , Baoqing Sun  1
Affiliations
Review

SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges

Mingtao Liu et al. Rev Med Virol. 2023 Sep.

Abstract

The COVID-19 pandemic represents an unparalleled global public health crisis. Despite concerted research endeavours, the repertoire of effective treatment options remains limited. However, neutralising-antibody-based therapies hold promise across an array of practices, encompassing the prophylaxis and management of acute infectious diseases. Presently, numerous investigations into COVID-19-neutralising antibodies are underway around the world, with some studies reaching clinical application stages. The advent of COVID-19-neutralising antibodies signifies the dawn of an innovative and promising strategy for treatment against SARS-CoV-2 variants. Comprehensively, our objective is to amalgamate contemporary understanding concerning antibodies targeting various regions, including receptor-binding domain (RBD), non-RBD, host cell targets, and cross-neutralising antibodies. Furthermore, we critically examine the prevailing scientific literature supporting neutralising antibody-based interventions, and also delve into the functional evaluation of antibodies, with a particular focus on in vitro (vivo) assays. Lastly, we identify and consider several pertinent challenges inherent to the realm of COVID-19-neutralising antibody-based treatments, offering insights into potential future directions for research and development.

Keywords: COVID-19; SARS-CoV-2; neutralising antibody.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48(2):155-163. https://doi.org/10.1007/s15010-020-01401-y
    1. Baker RE, Mahmud AS, Miller IF, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20(4):193-205. https://doi.org/10.1038/s41579-021-00639-z
    1. Haley WEISS. What to Know about the New XBB.1.16 COVID-19 Variant TIME. Accessed 21 April 2023. https://time.com/6268467/omicron-subvariant-xbb116-covid-19/
    1. Dhama K, Nainu F, Frediansyah A, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2022;16(1):4-14. https://doi.org/10.1016/j.jiph.2022.11.024
    1. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2. N Engl J Med. 2022;386(15):1475-1477. https://doi.org/10.1056/nejmc2201933

Publication types

Supplementary concepts

-